文献速递肿瘤 PET/CT核素与放射性配体治疗

基线常规影像阴性的前列腺癌复发患者中18F-氟妥昔司他PET/CT真阳性病灶:前瞻性3期多中心SPOTLIGHT研究结果

True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study.
PubMed 文献 · J Nucl Med · 2024-07-01

SPOTLIGHT研究(NCT04186845)纳入基线常规影像阴性、生化复发的前列腺癌患者,静脉注射296 MBq 18F-氟妥昔司他后50-70分钟行PET/CT,以组织病理学或随访确证影像为标准真相。171例可评估患者中,多数阅片判定的总检出率为95%(163/171;95%CI 91.0%-98.0%),确证检出率为64%(110/171;95%CI 56.7%-71.5%)。

要点

  • 基线常规影像阴性患者中18F-氟妥昔司他PET/CT总检出率达95%(163/171)。
  • 171例中110例至少1个真阳性病灶,确证检出率64%(95%CI 56.7%-71.5%)。
  • 前列腺切除术后患者真阳性病灶位于前列腺床8.3%、盆腔淋巴结28%、其他部位35%。

核心结论

  • 18F-氟妥昔司他在常规影像阴性的前列腺癌复发患者中常可发现真阳性病灶。
  • 18F-氟妥昔司他可能较常规影像更好地确定疾病复发部位并为挽救治疗决策提供信息,可能改善结局。

研究设计与样本

  • SPOTLIGHT研究(NCT04186845)为前瞻性3期多中心研究。
  • 生化复发的前列腺癌患者静脉注射296 MBq 18F-氟妥昔司他,50-70分钟后行PET/CT。
  • PET/CT结果由3名设盲的中心阅片者判读,以组织病理学或随访确证影像(CT、MRI、骨扫描或18F-氟环洛芬PET/CT)为标准真相验证。
  • 本分析纳入基线常规影像阴性、接受18F-氟妥昔司他PET/CT并有组织病理学或随访确证影像标准真相验证的全部患者,共171例。
  • 报告多数阅片数据(≥2名阅片者一致)。

主要发现

  • 多数阅片判定的总检出率为95%(163/171;95%CI 91.0%-98.0%)。
  • 171例中110例至少1个真阳性病灶,确证检出率为64%(95%CI 56.7%-71.5%)。
  • 前列腺切除术后组(133/171)中,至少1个真阳性病灶位于前列腺床者8.3%、盆腔淋巴结28%、其他部位35%。
  • 接受放疗组(36/171)中,真阳性检出位于前列腺者50%、盆腔淋巴结8.3%、其他部位36%。

关键数值与推荐

  • 检出率定义为至少1个PET阳性病灶的患者数除以可评估患者数。
  • 确证检出率定义为经标准真相验证至少1个真阳性病灶的患者占所有扫描患者(PET阳性与PET阴性扫描)的比例。
  • 检出率和确证检出率按既往治疗分层计算。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-rhPSMA-7.3 (18F-flotufolastat) is a high-affinity prostate-specific membrane antigen-targeted diagnostic radiopharmaceutical for PET imaging in patients with prostate cancer. Here, we report findings from the SPOTLIGHT study (NCT04186845), assessing the performance of 18F-flotufolastat PET/CT for identifying prostate-specific membrane antigen-positive lesions confirmed by standard of truth (SoT) in men with biochemical recurrence of prostate cancer and negative conventional imaging at baseline. Methods: Men with biochemical recurrence received 296 MBq of 18F-flotufolastat intravenously and then underwent PET/CT 50-70 min later. 18F-flotufolastat PET/CT findings were evaluated by 3 masked central readers and verified using histopathology or follow-up confirmatory imaging (CT, MRI, bone scan, or 18F-fluciclovine PET/CT) as the SoT. The present analysis evaluated all patients who had negative conventional imaging at baseline, underwent 18F-flotufolastat PET/CT, and had SoT verification by histopathology or follow-up confirmatory imaging to report detection rate (DR), which is the number of patients with at least 1 PET-positive lesion, divided by the number of evaluable patients, and verified DR (VDR), which is the proportion of patients with at least 1 true-positive lesion as verified by SoT, of all patients scanned (PET-positive and PET-negative scans). DR and VDR were calculated and stratified according to prior therapy. Majority read data (agreement between ≥2 readers) are reported. Results: In total, 171 patients with negative baseline conventional imaging and SoT by histopathology or post-PET confirmatory imaging were evaluated. By majority read, the overall 18F-flotufolastat DR among these patients was 95% (163/171; 95% CI, 91.0%-98.0%), and 110 of 171 of these patients had at least 1 true-positive lesion identified (VDR, 64%; 95% CI, 56.7%-71.5%). In the postprostatectomy group (133/171), 8.3% of patients had at least 1 true-positive lesion in the prostate bed, 28% in pelvic lymph nodes, and 35% in other sites. Among those who had received radiotherapy (36/171), 50% of patients had true-positive detections in the prostate, 8.3% in pelvic lymph nodes, and 36% in other sites. Conclusion: 18F-flotufolastat frequently identified true-positive prostate cancer lesions in patients with negative conventional imaging. 18F-flotufolastat may help to better define sites of disease recurrence and inform salvage therapy decisions than does conventional imaging, potentially leading to improved outcomes.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fleming MT, Hermsen R, Purysko AS, et al. True-Positive 18F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study. J Nucl Med. 2024. PMID: 38782456. doi:10.2967/jnumed.123.267271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。